Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study ...
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the ...
Biomea Fusion, Inc.: Biomea Fusion Announces Positive Topline Results from Ongoing Phase II ...
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response achiev ...